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Abstract
Viruses are the predominant infectious cause of asthma exacerbations in the developed world. In
addition, recent evidence strongly suggests that viral infections may also have a causal role in the
development of childhood asthma. In this article, we will briefly describe the general perception of
how the link between infections and asthma has changed over the last century, and then focus on
very recent developments that have provided new insights into the contribution of viruses to
asthma pathogenesis. Highlighted areas include the contribution of severe early life viral infections
to asthma inception, genetic determinants of severe viral infections in infancy, the differences in
innate and adaptive immune system cytokine responses to viral infection between asthmatic and
nonasthmatic subjects, and a potential vaccine strategy to prevent severe early life virally-induced
illness.
Background
Infections have been recognized to be a cause of asthma
exacerbations for over 100 years. In his landmark text-
book that heralded modern medicine, Sir William Osler
noted that among other asthma exacerbating factors such
as allergens and environmental changes, "every fresh
cold" could induce a paroxysm of disease [1]. During
Osler's time, viruses had not yet been isolated as infec-
tious agents, and in the first half of the twentieth century,
the "colds" or upper respiratory tract infections that
caused worsening of asthma symptoms were largely pre-
sumed to be caused by a hypersensitivity or allergy to the
bacteria that were considered to be responsible for these
infections [2]. This concept was accepted by some physi-
cians who attempted to desensitize patients who experi-
enced asthma exacerbations following respiratory tract
infections by administering allergy shots that contained
bacterial extracts [3]. Detractors of the bacterial allergy
theory pointed out that while extracts of environmental
allergens such as pollens or animal dander could produce
positive immediate skin test results in sensitive subjects,
bacterial extracts did not provoke such hypersensitivity
reactions [4].
Despite the inability of bacterial skin testing to confirm
hypersensitivity to these organisms, immunotherapy con-
taining bacterial extracts was used substantially in the
prophylaxis against asthma exacerbations from the 1920s
to the late 1950s [4,5]. Physicians who used this bacterial
immunotherapy strategy reported that the majority of
their patients had symptomatic improvement on this
treatment [3,5]. However, several well controlled trials in
the late 1950s and early 1960s revealed that immuno-
therapy to bacterial antigens was no more effective than
placebo, and there was a call to end this practice that was
widely heeded by the medical community [5-7]. A further
blow to the concept of bacterial allergy came with rand-
omized controlled-trials in the 1970s and 1980s which
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course of asthma exacerbations, suggesting that bacteria
were not pathogenic [8,9]. The bacterial allergy theory
presents an interesting irony in the history of immuno-
therapy when viewed in light of the hygiene hypothesis.
The hygiene hypothesis suggests that an early exposure to
bacterial products (i.e. endotoxin) may prevent subse-
quent allergic sensitization and asthma because the
immune system has been steered toward the Th1 pathway
of CD4 development and away from a Th2 phenotype. An
interesting test of the hygiene hypothesis would have
been to have given bacterial allergen immunotherapy
containing endotoxin to young children, rather than
adults as occurred in the randomized trials that proved
this form of immunotherapy was not efficacious in the
studied older population. The hygiene hypothesis would
predict that bacterial allergen immunotherapy might have
reduced allergic disease and asthma in children that
received this treatment.
To further determine if the presence of bacteria was asso-
ciated with worsening asthma symptoms, investigators
sought to identify if bacteria could be cultured from the
upper respiratory tract more often when patients were
symptomatic with asthma exacerbations, compared to
times when they were not. There was no difference in the
presence of bacterial infections when subjects were symp-
tomatic compared to when they were not, further suggest-
ing that bacteria were not responsible for asthma
worsening [10,11]. In contrast, studies using techniques
that are relatively insensitive for determining the presence
of viral infection of the upper respiratory tract, such as cul-
ture, immunofluorescence, and serology, revealed that
viruses were present from 2 to 5 times more frequently
when asthmatic subjects were in exacerbation compared
to when they were without symptoms [12-15].
By the mid 1990s, polymerase chain reaction (PCR) tech-
nology was being used in clinical research studies and
revealed that viruses could be detected in the respiratory
tract secretions of 80–85% of school children who were
experiencing asthma exacerbations [16]. Studies of adult
asthmatics also revealed that viruses could be detected in
subjects' respiratory tract secretions during 50–80% of
exacerbations [17]. In both school aged children and
adults, rhinovirus (RV) is the most common virus
detected during exacerbations [18,19]. Thus, we have
come full circle in that in the 1890s Osler recognized the
cold to be a major cause of asthma exacerbations and we
have now recently recognized that the etiologic agent
most often responsible for colds, rhinovirus, is also the
most frequent cause of asthma exacerbations. Now that
the historical perspective linking viral infection and exac-
erbations has been explored, we will focus on selected
papers published in the last two years which further eluci-
date the role and mechanisms of viral infections in
asthma development and pathogenesis.
Asthma inception
The role of viral infections in asthma inception in infants
and young children has been debated for many years. Wu
and colleagues found that birth timing in relationship to
the peak of hospitalization for bronchiolitis determines
the risk of severe bronchiolitis during infancy, as well as
the risk of developing asthma [20]. These findings suggest
that bronchiolitis, or some factor closely associated with
bronchiolitis, might cause asthma. In this investigation, a
cohort of over 95,000 children enrolled in the Tennessee
Medicaid program who were born between 1995 and
2000 was followed over their first five viral seasons until
the age of 5 1/2 years. This population represents approx-
imately one-quarter of the births each year in that state.
The authors conducted six analyses to determine how the
effect of infant birth date in relationship to the winter
virus peak might alter the risk of developing early child-
hood asthma.
First, the timing of infant birth in relationship to the winter
virus peak, as defined as the first day of the week with the
highest number of bronchiolitis hospitalizations for that
winter season, predicted the likelihood of developing clini-
cally significant bronchiolitis [21]. Clinically significant
bronchiolitis was defined as hospitalization, emergency
department visit, or outpatient visit. After adjusting for other
factors previously reported to be associated with severe bron-
chiolitis, infants 122 days (95% CI, 118–126 days) old at the
winter virus peak had the greatest risk of developing clini-
cally significant bronchiolitis (Figure 1). Second, the timing
of infant birth in relationship to the winter virus peak pre-
dicted the likelihood of developing childhood asthma as
defined by ICD-9 code or medication use for asthma. Chil-
dren who were 121 days (95% CI, 108–131 days) old at the
winter virus peak had the greatest risk of developing high risk
asthma when a comparison was made with children who
were either older or younger at the peak of the winter virus
season (Figure 2) [22]. High risk asthma was defined as
asthma-related hospitalization, emergency department treat-
ment, or rescue corticosteroid prescription. Despite the fact
that the winter virus peak shifted as much as six weeks over
the 5 viral seasons studied for each child, this relationship of
age at peak viral season with the subsequent development of
asthma was not affected when subgroup analysis was con-
ducted on children who encountered early or late winter
virus peaks. Surprisingly, maternal history of asthma had no
effect on this analysis.
In the third analysis, compared to children who were 365
days old at the winter virus peak, there was a 29% increase
in odds of developing high-risk childhood asthma for
children who were 121 days of age at the winter virusPage 2 of 9
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that conferred the greatest risk of bronchiolitis [23]. The
importance of age at the time of virus peak was further
strengthened by the fourth analysis which found that the
age at which a child first presented with bronchiolitis
symptoms had no bearing on the subsequent develop-
ment of asthma; however, the age of the child in relation-
ship to the peak of the viral season conferred an increased
likelihood of developing high risk asthma.
Fifth, despite the fact that smoking during pregnancy and
maternal asthma increased the odds of developing high
risk asthma by 7% and 82%, respectively, neither of these
factors significantly changed the relationship between
infant age at winter virus peak and childhood asthma
[24]. There were no interactions between infant age at the
winter virus peak and other covariates examined, such as
infant race, gender, birth weight, gestational age, other liv-
ing siblings, region of residence, and maternal education
on the risk of developing asthma [25].
Predicted probability and 95% confidence intervals of bron-chiolitis requiring a health care visit during infancy (hospitali-zation, emerge cy department visit, or outpatient visit) by infant age in months at the winter virus peak (  = 345.52; P < 0·001)Figure 1
Predicted probability and 95% confidence intervals of 
bronchiolitis requiring a health care visit during 
infancy (hospitalization, emergency department visit, 
or outpatient visit) by infant age in months at the 
winter virus peak (  = 345.52; P < 0·001). Results 
were obtained from a multivariable logistic regression model. 
Effect was adjusted for gender, infant race, birth weight, ges-
tational age, number of living siblings, region of residence, 
maternal smoking, marital status, maternal education, and 
season. Reprinted with permission from Wu et al, Am J 




2 Differential risk of developing current high-risk childhood asthma in relationship to infant age at the winter virus peakFigu  2
Differential risk of developing current high-risk child-
hood asthma in relationship to infant age at the win-
ter virus peak. Results were obtained from a multivariable 
logistic regression model adjusted for gender, infant race, 
birth weight, gestational age, number of living siblings, region 
of residence, maternal smoking, marital status, maternal edu-
cation, and season. (A) Predicted probability and 95% confi-
dence intervals (CI) of developing current high-risk 
childhood asthma by infant age in months at the winter virus 
peak (  = 49.05; P < 0·001). The area under the curve is 
equal to the asthma prevalence of the population. (B) 
Adjusted odds ratio and 95% CI of developing current high-
risk childhood asthma relative to children who were 12 
months of age at the winter virus peak. Infants who were 1 
year of age at the winter virus peak served as the reference 
group. Reprinted with permission from Wu et al, Am J 
Respir Crit Care Med 178:1123–1129, 2008.
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tions for the relationship between the timing of the peak
of the viral season and the increased risk of developing
both significant bronchiolitis and high risk asthma [26].
The first is that a common genetic predisposition could
lead to both severe winter viral bronchiolitis and asthma,
while the other is that an environmental exposure such as
winter viral infection leads to asthma. The data presented
does not rule out either or both of these possibilities. One
of the most interesting aspects of this study is the risk of
developing either bronchiolitis or asthma by timing of
birth in relationship to the winter virus peak was present
for every year analyzed, despite the fact that the timing of
the viral peak shifted from year to year. Thus, being born
around 4 months (120 days) before the peak of the viral
season confers a similar and significantly increased risk of
developing both bronchiolitis and subsequent asthma
[27].
Wu and colleagues did not determine the viruses respon-
sible for the peak of the viral season in their study [28];
however, other long-term longitudinal studies have
reported that respiratory syncytial virus (RSV) lower respi-
ratory tract infection increases the risk for subsequent
wheezing [29] and asthma [30] at least through age 10.
However, Jackson and colleagues have found that rhino-
virus infections that result in wheezing illness in the first
three years of life predict asthma development in children
that are deemed high risk because of a family history of
allergy or asthma, and that this risk surpasses that associ-
ated with early life wheezing from RSV infection [31]. In
this study, 259 children enrolled in the University of Wis-
consin Childhood Origins of Asthma (COAST) study were
followed prospectively for 6 years and had met entry cri-
teria because either one or both parents had a history of
positive skin tests to aeroallergens or physician diagnosed
asthma [32]. The presence of virus in respiratory tract
secretions in early life was determined by PCR and stand-
ard viral detection techniques at scheduled monthly inter-
vals during the first year of life and when subjects
developed respiratory tract illnesses. The assays incorpo-
rated potential detection for rhinovirus, RSV, parainflu-
enza virus types 1–4, influenza types A and B, adenovirus,
enterovirus, coronavirus, and metapneumovirus.
Analysis of respiratory tract secretions revealed that
viruses were present in these fluids 90% of the time that
wheezing illnesses occurred in the first three years of life
[33]. Rhinovirus was the virus most frequently detected
(48%), followed by RSV (21%), parainfluenza viruses
(12%), with the other viruses being detected in less than
10% of the respiratory tract secretions. In approximately
10% of wheezing illnesses, more than one virus was
detected in the respiratory tract secretions. In this high risk
population, 28% of the subjects met the criteria for
asthma diagnosis at age 6 based on National Asthma Edu-
cation and Prevention program guidelines. When an anal-
ysis was performed to determine which viruses were most
often detected in the respiratory tract secretions during
wheezing illnesses before age three and associated with
the diagnosis of asthma at age 6, rhinovirus was the most
common virus identified. The odds ratio of having asthma
at age 6 was 9.8 for rhinovirus, and 2.6 for RSV, respec-
tively, when these viruses were detected during wheezing
illnesses that occurred at age 3 or before (Figure 3). The
referent was neither RSV nor RV being detected in the
nasal secretions. When both rhinovirus and RSV were
detected, the odds ratio of having asthma at age 6 was
10.0. Wheezing illness with none of the other viruses
included in the viral detection assays was associated with
asthma diagnosis at age 6.
The authors also analyzed the data based on the viruses
detected at each year up to age 3 and the subsequent risk
of developing asthma at age 6 [34]. They found that rhi-
novirus detection in the respiratory tract secretions during
wheezing illness during the first year of life was associated
with a statistically significant increased odds ratio (2.7)
for having an asthma diagnosis at age 6, and this was com-
parable to the odds ratio (3.6) of having asthma at age 6
that was associated with skin test positivity to aeroaller-
gens. There was a further increase in the odds ratio of hav-
ing asthma at age 6 associated with rhinovirus in the
respiratory tract secretions during wheezing illnesses at
age 2 (OR 6.5) and age 3 (31.7). In contrast, there was no
increase in the odds ratio of having asthma at age 6 with
Risk of asthma at age 6 years in children who wheezed during the first 3 years of life with rhinovirus (RV), respiratory sy -cytial virus (RSV), or both (*P < 0.05 vs. Neither; +P < 0.05 vs. RSV only)F gu e
Risk of asthma at age 6 years in children who 
wheezed during the first 3 years of life with rhinovi-
rus (RV), respiratory syncytial virus (RSV), or both 
(*P < 0.05 vs. Neither; +P < 0.05 vs. RSV only). OR = 
odds ratio. Reprinted with permission from Jackson et al, Am 
J Respir Crit Care Med 178:667–672, 2008.Page 4 of 9
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age 2, and an increased odds ratio with RSV detection was
only seen in the third year of life (9.9). One could make
the strong argument that while wheezing at age 1, and per-
haps at age 2, may most likely represent bronchiolitis,
virally-induced wheezing at age 3 may more likely reflect
an exacerbation of asthma. Of note, subjects with acute
RV infection associated with wheezing from age 1–3 years
had a 59% asthma risk at age 6 [35]. In any case, this study
proposes that rhinovirus infection in early life may be
causative for the subsequent development of asthma and
that future studies examining the relationship between
infant infections and asthma needs to include assays for
the detection of rhinovirus and the inclusion of this virus
in the data analysis [36].
Genetic susceptibility to bronchiolitis
As noted above, early life rhinovirus and RSV are associ-
ated with the subsequent development of asthma. The rec-
ognition that rhinovirus may have an important role in
the inception of asthma is a novel concept, first put for-
ward by Jackson and colleagues as just reviewed [37].
Therefore genetic association studies examining the host
risk factors for severe rhinovirus infection in early life have
not yet been performed. However, there has been a great
deal of interest in genetic determinants of severe RSV-
induced disease, mainly because of the concept that the
host immune response is a large determinant of severity of
illness, although as we will mention later viral determi-
nants may also have an important contribution to disease
severity. Over the last several years, genetic association
studies suggest that variation in specific genetic loci confer
susceptibility to RSV-induced illness. Host response genes
that have been associated with RSV disease include sur-
factant protein A, surfactant protein D, toll like receptor
(TLR) 4, tumor necrosis factor (TNF), interleukin (IL)-4,
IL-9, IL-10, IL-8, IL-13, and RANTES [38-45]. Recently,
Janssen and colleagues performed a large scale genotyping
study in the Netherlands using a candidate gene approach
to identify potentially new genes and biologic pathways
that contribute to susceptibility to severe RSV infection
[46]. They reported that genetic susceptibility to RSV is
predominantly associated with innate immune genes. In
their analysis, these investigators performed a genetic
association study in 470 children who had been hospital-
ized for RSV bronchiolitis. In order to rule our potential
confounding factors, children with a history of airway
morbidity, airway medication, and wheeze were excluded
from the study. In the analysis, the enrolled children's par-
ents and 1008 random, population controls were also
included.
Janssen reported that 22 single nucleotide polymor-
phisms (SNPs) in 21 genes were identified that were sta-
tistically significantly associated with severe RSV disease at
either the genotype or allele level [47]. Those SNPs associ-
ated with severe RSV disease both at the genotype and
allele level included the genes for the vitamin D receptor
(VDR), the signal transduction molecule Jun (JUN) which
composes part of the AP-1 signaling complex, interferon
(IFN)-α (IFNA5) which is a type I IFN involved in early
cytokine responses to viral infection, inducible nitric
oxide synthase (NOS2A), and the high affinity IgE recep-
tor (FCER1A) important in IgE binding to mast cells,
basophils, dendritic cells, and other immune cells.
SNPs were also discovered that were associated with severe
RSV disease at the allele level [48]. Based on the function of
the gene products, the investigators divided the SNPs into
four subgroups: innate immunity (IFNA13, IL15, STAT1,
and TLR8), chemotaxis (CCL8, ITGB2, and VCAM), adaptive
immunity (CD28 and STAT1), and allergic asthma (MS3A2,
ADAM33, IL4R, and IL9R). Those SNPs that had an associa-
tion with RSV at the genotype level only were present in
genes involved in innate immunity (TNF and NCF2) and
adaptive immunity (IL10, IL4R, and IL17).
This study is an important contribution to our scientific
knowledge of RSV-induced illness because it provides can-
didates for future genetic analysis, haplotype determina-
tion, and functional studies to further define the
contributing factors that are responsible for severe disease.
In addition, the data reveal that genetic susceptibility to
RSV bronchiolitis is a very complex trait with host
response genes being strong contribution factors.
Cytokine responses to viral infection
As just mentioned above, genes associated with severe
RSV disease in infancy, and perhaps asthma inception,
include those that are involved in cytokine production
(IFNA13, IL15, IL10, and IL17) and cytokine receptor sig-
naling (IL4R,IL9R, and STAT1). Since there is a very high
percentage of asthmatic children who are atopic, one
could hypothesize that those children who have RSV
bronchiolitis in infancy and who subsequently develop
asthma have increased levels of Th2 cytokines compared
to children who experience RSV bronchiolitis, but that are
not diagnosed with asthma. Castro and colleagues tested
this hypothesis in a prospective cohort of 206 previously
healthy children who had been enrolled in the RSV Bron-
chiolitis in Early Life (RBEL) study [49]. As opposed to the
COAST study mentioned earlier [50], these children were
not preselected based on a family history of allergy or
asthma [51]. Despite this, there was an extraordinary high
percentage (48%) of children enrolled in RBEL who were
physician diagnosed with asthma at age 6. Thirty-two per-
cent of children had positive skin tests at age 3; however,
there was not an RSV-uninfected group that could serve as
controls to determine how the allergic sensitization rate
varied based on early infant severe RSV infection. Con-Page 5 of 9
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ence in cytokine generation between those children who
had severe RSV bronchiolitis and who developed asthma
and those who were not given an asthma diagnosis. At age
6 years, asthmatic children who had experienced severe
RSV infection during infancy actually had decreased IL-13
levels (defined by peripheral blood T cells that were stim-
ulated with phorbol and ionomycin) compared to nonas-
thmatic subjects. In addition, there were no differences in
IFN-γ, IL-2, or IL-4 levels from stimulated T cells between
the asthmatic and nonasthmatic groups [52]. However,
other studies suggest that cytokine responses occurring
during bronchiolitis do predict subsequent asthma devel-
opment. For instance, Renzi and colleagues found that
infants with later possible and probable asthma had
decreased peripheral blood mononuclear cell production
of IFN-γ during bronchiolitis [53].
The cytokine profile produced in bronchiolitis is very dif-
ferent from that which occurs with virally-induced asthma
exacerbations. Message and colleagues performed a study
in which they experimentally infected 10 asthmatic sub-
jects and 15 nonasthmatic subjects with rhinovirus and
then examined pulmonary function and cytokine
responses in CD4 cells from peripheral blood and bron-
choalveolar lavage fluid [54]. They report that asthmatic
subjects had significantly increased chest symptoms, a
greater fall in the forced expiratory volume in 1 second
(FEV1) and peak expiratory flow (PEF), and heightened
methacholine reactivity in response to experimental rhi-
novirus infection compared to the nonasthmatic subjects.
In regard to cytokine responses, persons who had greater
IFN-γ and IL-10 production by peripheral blood CD4 cells
had decreased viral loads and decreased upper respiratory
tract symptoms. Similarly, those subjects with greater IFN-
γ production by CD4 cells obtained by BAL were protected
from falls in PEF after rhinovirus infection, while those
subjects whose BAL CD4 cells produced higher levels of
the Th2 cytokines IL-4, IL-5, and IL-13 all had increased
lower respiratory symptom scores. In addition, after rhi-
novirus infection, BAL cells from asthmatic subjects were
deficient in the production of IFN-γ, IL-10, and IL-12,
while producing greater Th2 cytokine levels. In contrast
rhinovirus infection resulted in induced IFN-γ, IL-10, and
IL-12 from the nonasthmatics' BAL CD4 cells, while there
was no increase in Th2 cytokines in this group [55]. This
data fits very well with prior reports from this group which
suggests that there are significant defects in the cytokine
responses of the innate immune system in asthmatic sub-
jects compared to nonasthmatics. These investigators pre-
viously showed that the airway epithelium from
asthmatics produced significantly decreased amounts of
type I [56] and type III interferons [57] in response to rhi-
novirus infection compared to the epithelial cells from
nonasthmatics. This same group has also recently
reported that rhinovirus infection of epithelial cells results
in a dramatic increase in pro-inflammatory cytokine pro-
duction with near concurrent exposure to the major aller-
gen from the dust mite species Dermatophagoides
pteronyssinus [58]. In this study, the immortalized line of
human bronchial epithelial cells, BEAS-2B, were exposed
to rhinovirus, dust mite antigen, or both. When rhinovi-
rus infection occurred 24 hours prior to dust mite expo-
sure, there was a synergistic increase in epithelial cell
production of IL-8, an important neutrophil chemotactic
and survival factor. This rhinovirus/dust mite exposure
pattern was associated with early synergistic NF-kB trans-
location induction, perhaps explaining the augmented IL-
8 release. There was also increased expression of the adhe-
sion molecule ICAM-1, which serves as the major rhinovi-
rus receptor on epithelial cells. This synergism in IL-8
expression and NF-kB translocation was not observed
when epithelial cell dust mite exposure occurred prior to
rhinovirus infection, suggesting that the timing of these
exposures is critical to cytokine elaboration [59].
Therapy
As early life severe viral infection has been linked to
asthma inception, preventing such episodes would per-
haps decrease the incidence and prevalence of asthma.
Unfortunately there is no currently available FDA-
approved vaccine against RSV. However, a recently com-
pleted trial provides hope that such a vaccine approach
may soon be available. Wright and colleagues report that
388 study subjects were examined and divided into one of
three groups: children that received one of several live,
attenuated RSV vaccines, children administered placebo
vaccine, and age-matched controls [60]. Subjects that were
vaccinated with the live, attenuated RSV vaccines had a
significant decrease in RSV-associated upper respiratory
tract illness compared to those that were administered a
placebo or nonvaccinated subjects. Results stratified for
subject age revealed that RSV-associated upper respiratory
tract illness occurred in 6–24 month old children with a
frequency of 14% in those receiving the RSV vaccine and
in 20% of the controls. When infants were examined, 16%
of those vaccinated with the RSV vaccine had RSV-associ-
ated upper respiratory tract illness compared to 25% in
the control groups. While these results are promising,
there are some caveats that need to be considered. First,
the study was not randomized, nor was it blinded. Sec-
ond, the dates of surveillance ranged over the period from
1994–2003 and incorporated seven different live, attenu-
ated vaccines. However, it is important to note that the
RSV vaccines did not result in the enhanced illness after
naturally occurring infection that was seen in children
who had previously received an alum-precipitated, forma-
lin-inactivated vaccine in the late 1960s [61].Page 6 of 9
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tial novel therapy, other studies suggest that prophylactic
anti-RSV immunoglobulin may affect the later develop-
ment of asthma. Simoes reported that palivizumab, an
anti-RSV monocolonal antibody, reduced subsequent
wheezing in preterm infants [62]. In a retrospective anal-
ysis, Wenzel and colleagues found that children at risk for
RSV bronchiolitis that were treated with RSV-immune
globulin had a decreased incidence of obstructive airway
disease, ever having an asthma exacerbation, and atopic
disease as defined by skin testing to aeroallergens, com-
pared to a control group that did not receive RSV immu-
notherapy [63]. To fully understand the effect of anti-RSV
immunoflobulin on the later development of allergic dis-
ease and asthma, a prospective, randomized, double-
blinded, placebo-controlled trial needs to be conducted.
Summary
Although bacterial infections were long considered to the
primary infectious agents linked to asthma pathogenesis,
over the last decade, new data supports that virus infec-
tions are the cause of a great majority of asthma exacerba-
tions. New data published in the last year strengthens
earlier reports that early life viral infections may have a
significant role in asthma inception. Gene association
studies reveal that persons with deficiencies in innate
immunity may be more predisposed to these severe early
life episodes of viral bronchiolitis that predispose to the
later development of asthma. Deficiencies in innate
immunity are also present in adult asthmatics compared
to their nonasthmatic counterpart as witnessed by the dif-
ference in cytokine responses in peripheral blood and BAL
CD4+ cells following rhinovirus infection and in the epi-
thelial cells responses to viral challenge. Prevention of
early life severe bronchiolitis episodes is a major priority
and vaccine approaches are being developed to fill this
therapeutic need. Further research and therapeutic strate-
gies are needed to advance our understanding of the con-
tribution of viruses to asthma pathogenesis and protect
against both the inception and exacerbations of this dis-
ease.
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